T3D Therapeutics
2013
FOUNDED
PRIVATE
STATUS
1-10
EMPLOYEES
Series B
LATEST DEAL TYPE
$15M
LATEST DEAL AMOUNT
1
INVESTORS
Description
Developer of a novel drug therapy intended to stop or reverse the course of Alzheimer's disease. The company's drug is an orally-delivered once-a-day medicine that targets both the brain 'starvation' and neurodegeneration of Alzheimer's disease and helps in treating multiple manifestations of the disease, providing Alzheimer patients with a drug to potentially improve multiple defects and improve memory, motor function and cognition.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Primary Office
- 68 T.W. Alexander Drive
- P.O. Box 13628
- Research Triangle Park, NC 27709
- United States
+1 (919) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore T3D Therapeutics’s full profile, request a free trial.
T3D Therapeutics Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC (Series B) | 04-Nov-2019 | $15M | 000.00 | Completed | Generating Revenue | |
| 8. Grant | 20-May-2019 | 000 | 000.00 | Completed | Clinical Trials - Phase 2 | |
| 7. Early Stage VC (Series B) | 10-Mar-2018 | 000 | 000.00 | 0000 | Completed | Clinical Trials - Phase 2 |
| 6. Early Stage VC (Series A3) | 11-Mar-2016 | 00.000 | 00.000 | 0000 | Completed | Clinical Trials - Phase 2 |
| 5. Grant | 24-Mar-2015 | 00.000 | 00.00 | Completed | Clinical Trials - Phase 2 | |
| 4. Debt - General | 31-Jul-2014 | 00000 | 00.00 | Completed | Startup | |
| 3. Early Stage VC (Series A2) | 14-Mar-2014 | 00000 | 00.000 | 00.000 | Completed | Startup |
| 2. Debt - General | 24-Jun-2013 | $50K | $487K | Completed | Startup | |
| 1. Angel (individual) | 20-Jun-2013 | $437K | $437K | 00.000 | Completed | Startup |
T3D Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series A3 | 0,000,000 | 00.000000 | 00 | 00 | 00 | 00 | 00 | 0.000 |
| Series A2 | 000,000 | 00.000000 | 00 | 00.0 | 00.0 | 00 | 00.0 | 0.000 |
| Series A1 | 404,628 | $0.001000 | 6% | $1.08 | $1.08 | 1x | $1.08 | 7.26% |
T3D Therapeutics Competitors (29)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Yumanity Therapeutics | Venture Capital-Backed | Cambridge, MA | 00 | 000.00 | 0000000000 0 | 000.00 |
| 0000000 | Venture Capital-Backed | Framingham, MA | 0 | 0000 | 00000000 | |
| 00000 000000000000 | Formerly VC-backed | Cambridge, MA | 000.00 | 000000&0 | 000.00 | |
| 00000 | Venture Capital-Backed | Pittsburgh, PA | 00 | 000.00 | 0000000000 0 | 000.00 |
| 000000000 | Formerly VC-backed | South San Francisco, CA | 00 | 00000 | 00000000 | 00000 |
T3D Therapeutics Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| National Institute On Aging | Government | 000 0000 | 000000 0 |
T3D Therapeutics Executive Team (3)
T3D Therapeutics Board Members (5)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Barry Buzogany JD | T3D Therapeutics | Board Member | 000 0000 | |
| Charles Lineberry Ph.D | T3D Therapeutics | Board Member | 000 0000 | |
| John Didsbury Ph.D | T3D Therapeutics | Founder, Chairman of the Board, President & Chief Executive Officer | 000 0000 | |
| John Golden | Self | Board Member | 000 0000 | |
| Thomas Mendell | Self | Board Member | 000 0000 |